Moleculin
  • About
    • About Us
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnership Inquiries
  • Pipeline
    • Overview
    • Annamycin
    • WP1122
    • WP1066
    • WP1220
    • Disease Areas
      • Acute Myeloid Leukemia (AML)
      • Soft Tissue Sarcoma (STS)
    • Scientific Publications and Presentations
  • Clinical Studies
    • MIRACLE: Pivotal, Adaptive Phase 3 Study in AML
    • MB-107: Phase1B/2 Study in STS Lung Mets
    • Completed: MB-106 Phase 1B/2 Study in AML
    • Expanded Access
  • Investors
    • Overview
    • News
    • Events
    • Presentations
    • Analyst Coverage
    • Company Info
      • Profile
      • Management
      • FAQ
    • Investor Contacts
    • Financial Info
    • Annual Report and Proxy
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Contact
Select Page
  • Overview
  • News
  • Events
  • Presentations
  • Analyst Coverage
  • Company Info
    • Profile
    • Management
    • FAQ
  • Investor Contacts
  • Financial Info
  • Annual Report and Proxy
  • Stock Data
  • SEC Filings
  • Governance
  • Email Alerts

Investors: Annual Report and Proxy

5300 Memorial Drive, Suite 950
Houston, TX, 77007
info@moleculin.com
(713) 300-5160

Sign Up For Alerts
Contact Us:
info@moleculin.com
  • Follow
  • Follow
  • Follow
Copyright © 2025 Moleculin. All Rights Reserved

Privacy Policy    Disclaimer

5300 Memorial Drive, Suite 950 |Houston, TX, 77007
info@moleculin.com
(713) 300-5160

Sign Up For Alerts

Contact Us:
info@moleculin.com

  • Follow
  • Follow
  • Follow
Copyright © 2025 Moleculin, Inc. All Rights Reserved

Privacy Policy  Disclaimer